Elena Castro retweeted
🚨 Major shift: @AmericanCancer now directly recommends routine PSA screening for #prostatecancer, moving off pure shared decision-making 🚨
@CACancerJournal
📋 Average risk: PSA every 2 yrs, ages 50-69
📋 High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69
📋 Non-Black w/ one first-degree relative dx ≥65: every 2 yrs, ages 45-69
🔬 Age-adjusted elevated = PSA ≥3.0 (ages 45-69) or ≥6.5 (70-74); repeat in 2 wks to 3 mo, then MRI and/or validated biomarker before biopsy
🛑 70-74 individualized; not recommended ≥75 or if life expectancy <10 yrs
⚠️ Still requires informed consent on benefits, limits, and harms, and departs from USPSTF’s grade C for 55-69
🎯 ACS has moved from “discuss it” to “do it” for average-risk men 50-69 and high-risk men from 45, its biggest change since 2010
🔗 doi.org/10.3322/caac.70112
@UroOnc @urotoday @UrologyTimes @PCF_Science @AmerUrological
Elena Castro retweeted
1/9 Our latest manuscript from the #CAPTURE platform in advanced #ProstateCancer is published in @EurUrolOncol. The prognostic impact of BRCA2 gene alterations has been well established, but is BRCA1 comparable to BRCA2? Are all non-BRCA HRR alterations equivalent? 🧵
Elena Castro retweeted
In a randomised phase 2 trial, patients with metastatic hormone sensitive prostate cancer treated with PARP inhibitor talazoparib combined with androgen receptor inhibitor enzalutamide had an improved PSA response vs enzalutamide alone. dlvr.it/TVz69C @quimmateo @VHIO
Elena Castro retweeted
Our #ZZFIRST trial is out today in @NatureMedicine! An academic randomized phase II trial of Talazoparib + Enzalutamide in high-volume mHNPC integrating spatial transcriptomics on longitudinal tumor biopsies. Thanks to all patients and funding from DoD/CDMRP + @ContraCancerEs
Elena Castro retweeted
🌏 Global collaboration drives progress in GU oncology.
Join the conversation at #ESMOGUAsia27 and share your latest research with experts from across Asia and the world.
📅 Abstract deadline: 13 October
👉 ow.ly/iOXJ50ZTNTP
#ESMOMeetings #GUOncology
Elena Castro retweeted
🚨active surveillance, for #prostatecancer, now with a 25-year horizon🚨
@EUplatinum
📊 GÖTEBORG-1, screen-detected low- and intermediate-risk PCa, f/u up to 25 yrs
✅ extended data continue to support AS as safe for well-selected pts over the very long term
⚠️ intermediate-risk selection and adherence to follow-up still matter, this is screen-detected disease
⭐️PCa-specific survival at 25 yrs was 94%
-99% for VLR
-92% for LR
-85% for Int Risk
🎯 bottom line: when we tell a pt w/with low-risk PCa that surveillance is safe, we can now point to a quarter century of trial follow-up.
🔗 shorturl.at/H2a6x
#pcsm @AmerUrological @UroOnc @GGiannarini @PCFnews @PCF_Science @GabeCanales @ASPI_INTL
Elena Castro retweeted
🚨 ~90% 9-yr cancer-specific survival in very high-risk #prostatecancer.
❓The question is no longer "can we cure?" It's "at what cost?" 💸
👏 @CedricPetersRT et al: measure who's alive, failure-free, AND living well. One endpoint. Patient-centered.
⚖️ Our job now: personalize care. Less overtreatment for the many we cure. Less undertreatment for the few we miss.
🎯Cure alone isn't success.🎯
@PCFnews @PCF_Science @EurUrolOncol @Movember
🔗shorturl.at/VK7lL
Elena Castro retweeted
🎤Our very own @mroupret & @Ric_Campi chats with @declangmurphy and @RenuEapan, hosts of @gu_onc and its spin off, European Urology Podcast.
buff.ly/oyf9TzG or listen wherever you find your podasts
Watch on You Tube: buff.ly/qZPZ7dk
📢Papers highlighted in this podcast include:
🩺Expanding Risk-adapted Early Detection of Prostate Cancer: A Call to Action for Men at High Risk by Maike K. Klett...Alicia K. Morgans et al
buff.ly/GKHLmIF
🩺Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective by Igor Duquesne...François Audenet et al
buff.ly/W6qEsXb
🩺Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study by Chiara Re...Grant D. Stewart et al
buff.ly/3POVmI6
🩺Improved Shared Decision-making for Patients with Renal Cell Carcinoma: Results of the SDM-RCC Study by Cato C. Bresser...Paul B. van der Nat et al (for the SDM-RCC Study Group)
buff.ly/43Jcevo
@uroweb
@GPloussard
@jteoh_hk
@CaPsurvivorship
@LauraMarandino
@Ecastromarcos
@OncoAlert
@Sciencedirect
Enjoy!
Although rare, some CDK12 variants found in prostate tumors have a germline origin. Usually associated to a family history of PC or ovarian cancer.
Now online: Germline CDK12 variants in aggressive prostate cancer doi.org/10.1158/2159-8290.CD…
Elena Castro retweeted
🚨 🚨🚨New Editorial in @EurUrolOncol !
#PROTEUS trial: a landmark study, but are we ready for treatment intensification in high-risk PCa?
We discuss the evidence, unanswered questions, biomarkers, and the evolving role of multimodal care.
sciencedirect.com/science/ar…
Elena Castro retweeted
Breaking news #ASCO26 👉Ph3 PROTEUS trial👉Periop ADT + apalutamide in high-risk localized/locally advanced #prostatecancer undergoing radical prostatectomy👉↑ pathologic response (8.9% vs 1.0%) & 5-yr metastasis-free survival (78.2% vs 73.5%; HR 0.80) @urotoday @OncoAlert
Elena Castro retweeted
Replying to @Dolmos77
@Dolmos77 insightful discussant & first I’ve seen do a pooled analysis of 2 prior oral pres 👏. The point on earlier + earlier exposure to PARPi & risk of long-term tox is real when treated for yrs in #mHSPC. Needs to be looked at with earlier #PSMA RLT too?
#ASCO26 @OncoAlert – at Chicago, IL
Elena Castro retweeted
Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ
Elena Castro retweeted
AR + PARP intensification strategy in mHNPC by #JoaquinMateo in ZZFIRST: EZ+talazoparib achieved a 73% 12-mo PSA <0.2 response rate, with encouraging trends in rPFS and time to castration resistance. Translational analyses also highlighted biologic adaptation to AR inhibition.
#ASCO26 #ProstateCancer
@OncoAlert @ASCO @OncBrothers
Elena Castro retweeted
Lutetium-177 PSMA RLT has shifted the paradigm in mCRPC, but we always need a reality check
🔬 The Good: Unparalleled theranostic precision: tumour shrinkage, major Quality of Life improvements
🛑 The Catch: Disease recurrence remains virtually inevitable. Why? It struggles to suppress micrometastatic or heterogeneous disease.
🔮 The Future: Moving to earlier-line therapy, adaptive dosing, & next-gen alpha or Auger-electron emitters (like Terbium-161 and Lead-212).
The goal? Turning favourable initial responses into durable cures.
Full insights just published in European Urology Focus 👇
authors.elsevier.com/a/1nBKS…
Elena Castro retweeted
✍️ Some reading suggestons for your pleasure.
Find all the articles on our website buff.ly/uL9mjnW
➡️ Prognosis of Gleason Score 9–10 Prostatic Adenocarcinoma in Needle Biopsies: A Nationwide Population-based Study by Lars Egevad
➡️ PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-co hort
Replication Study Across Three Centers by Tolou Shadbahr et al
➡️ Single Port Robotic Radical Prostatectomy: A Propensity-matched Comparison of Transvesical Versus Extraperitoneal Approaches from the Single Port Advanced Research Consortium by Nicolas A. Soputro et al
We thank the authors for trusting EUO with your work!
@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect
📣Applications to the 2026 ESMO preceptorship on prostate cancer are open until 22 June‼️
Join us in Zurich 16-17 Sept. Complementary registration and accommodation are provided. @myESMO
esmo.org/meeting-calendar/es…
Elena Castro retweeted
APCCC 2026 supports closer imaging in mHSPC with BRCA1/2 or PTEN/TP53/RB1 alterations.
@ProfKHerrmann @DrMHofman @stefanofanti4 @ProfPadhani
@OncoAlert @APCCC_Lugano #APCCC26 @BourlonMaite @nataliagandur @Silke_Gillessen @AOmlin @OpenMedicineHQ @MedwatchKate
@Ecastromarcos @ravikanesvaran @dmukherji @scserendipity1 @CParkMD
@ZilliThomas @urotoday @Uroweb @CaPsurvivorship

















































